• Nabina Maharjan.
• Department of Microbiology, Lumbini Medical College and Teaching Hospital, Tansen, Palpa, Nepal.
• JNMA J Nepal Med Assoc. 2022 Aug 1; 60 (252): 676680676-680.

IntroductionCarbapenems resistance due to metallo-beta-lactamase production in Pseudomonas aeruginosa is a major concern which is increasing globally resulting in limited therapeutic choices. This study aimed to find out the prevalence of Pseudomonas aeruginosa isolates among clinical samples showing growth of a tertiary care centre.MethodsA descriptive cross-sectional study was conducted on various clinical samples which showed growth in the Department of Microbiology of a tertiary care centre between 1 September 2020 to 28 February 2021 after receiving ethical approval from the Institutional Review Committee (Reference number: 03-G/020). Convenience sampling was done. All timely received clinical specimens were inoculated and incubated at 37°C for 48 hours and identified by standard microbiological techniques. Point estimate and 95% Confidence Interval were calculated.ResultsAmong 1049 clinical samples showing growth, 68 (6.48%) (4.99-7.97, 95% Confidence Interval) Pseudomonas aeruginosa were isolated. Among them, 6 (8.82%) were found to be metallo-beta-lactamase positive.ConclusionsThe prevalence of Pseudomonas aeruginosa was similar to the studies done in similar settings. As metallo-beta-lactamase production was detected among isolated species which can be spread very rapidly and may develop a problematic scenario in treatment procedures, regular surveillance along with judicious use of carbapenems should precede.Keywordsbeta-lactamase; multidrug resistant; Pseudomonas aeruginosa.

14 keywords...

hide…